Revalor-G

Quick links to important sections

Revalor-G

Method of action: Endocrine Therapy

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Revalor-G

Property Description
Active ingredient Estradiol and Trenbolone acetate
Form Subcutaneous Implant (Pellet)
Pharmacological class Anabolic Agent / Sex Hormone
General purpose Increased weight gain and feed efficiency in cattle
Origin Synthetic Hormone

What Type of Combination Hormonal Agent is Revalor-G?

Revalor-G is a highly specialized veterinary combination product classified as a hormonal growth promotant, utilized exclusively within the beef cattle production sector. Its high-level pharmacological classification is an anabolic agent and sex hormone. The product is synthesized from steroid derivatives, confirming its nature as a synthetic compound. Its composition is fixed, containing two distinct active ingredients: Estradiol (17beta-estradiol) and Trenbolone acetate (17beta-trenbolone). The combined, dual-hormone strategy employed in Revalor-G is clinically recognized for maximizing anabolic outcomes in production animals, distinguishing it from single-agent steroid formulations.

The Physical Form: A Subcutaneous Extended-Release Implant

The delivery of the active ingredients is achieved via its specific dosage form, which is a solid, compressed subcutaneous implant or pellet. This form dictates the route of administration, ensuring the implant is placed beneath the skin, typically in the ear. The implant is engineered as an extended-release formulation, a key differentiating feature designed to sustain the delivery of the Estradiol and Trenbolone acetate into the animal's system at a controlled rate over a prolonged period. This slow-release mechanism is essential for maintaining consistent systemic exposure, which is necessary to maximize the product's intended physiological effects throughout the feeding cycle.

General Purpose and Anabolic Action

The overarching purpose of Revalor-G is to enhance the productive metrics of feedlot cattle, specifically by achieving increased weight gain and superior feed efficiency. The combined presence of the two hormones induces a strong anabolic drive, which encourages the formation of new tissue mass, primarily by promoting protein synthesis and the retention of nitrogen in muscle cells. This targeted hormonal manipulation facilitates nutrient repartitioning, actively shifting the animal's metabolism to direct a greater proportion of consumed dietary energy toward the accumulation of lean muscle mass in the target audience.

Regulatory References

  1. FDA Classification NADA 140-992

What side effects are possible with Revalor-G?

Possible Side Effects and Safety Information

The safety profile for Revalor-G (trenbolone acetate and estradiol implants) is defined by officially documented hormonal effects in cattle and specific regulatory constraints on its use. The adverse reactions reported are primarily related to the product's classification as an anabolic agent and sex hormone, as detailed in governmental labeling.

Documented Adverse Reactions

The most commonly observed effects are manifestations of hormonal activity, generally described in regulatory documents as events that may occur or have been occasionally reported. In heifers, these include signs such as edema of the vulva and udder, teat elongation, udder development, and in some cases, rectal or vaginal prolapse. In steers, the documented effects include delayed testicular development and signs of bulling (mounting behavior).

Additionally, safety information addresses local adverse reactions at the site of administration, noting that abscess formation may occur if proper hygiene is not maintained during the subcutaneous implantation procedure.

Critical Regulatory Safety Constraints

The regulatory label establishes strict limitations regarding the product's use in specific populations, primarily to ensure consumer safety and product efficacy:

  • Prohibited Populations: The product is not approved for use in young calves (e.g., beef calves under 2 months of age, dairy calves, veal calves) or in dairy cows.
  • Reproductive Safety: It must not be used in any animals intended for subsequent breeding.
  • Administration Rules: The implant pellets must be placed subcutaneously in the ear only; use in any other location is prohibited. Furthermore, re-implantation of the product is not approved.

When Revalor-G is administered strictly according to these official labeling requirements, the product has a documented no withdrawal period.

Overdose and Emergency Response

The regulatory information concerning Revalor-G overdose focuses primarily on the actions required following accidental human exposure to the subcutaneous implant, such as self-injection or ingestion. Official documentation mandates that any individual experiencing accidental exposure must seek immediate medical attention.

The official profile does not explicitly detail specific clinical signs or symptoms of human overdose resulting from exposure to this combination veterinary product. In situations where exposure occurs, hospital monitoring may be required to manage potential systemic effects.

Management is defined by the absence of a specific countermeasure. Regulatory authorities note that no specific antidote is known for the active ingredients, Estradiol and Trenbolone acetate, in this context. Consequently, any medical approach must center on symptomatic and supportive treatment.

Because specific overdose manifestations are not detailed in the product's official human safety information, immediate contact with emergency services is necessary upon exposure to ensure compliance with government-stated guidance for serious scenarios. This approach reflects the structured response required by regulatory authorities for managing human risk associated with animal drug products.

Therapeutic Uses of Revalor-G

What Revalor-G Treats: Main Uses and Benefits

Revalor-G is generally used in specialized beef production contexts where supportive assistance for growth performance is appropriate. This product is applied in clinical settings to help manage symptomatic patterns related to growth rate in growing beef steers and heifers. This therapeutic focus is aligned with domains where symptomatic assistance for growth metrics is relevant.

It is commonly used to help manage the symptomatic pattern of suboptimal weight gain rate and poor feed efficiency in animals that may be consuming lower-energy forage on pasture. The product is also relevant in clinical situations characterized by the insufficient development of lean muscle tissue. Its use supports the promotion of quality mass accumulation, which may assist with maintaining a desirable final live weight.

“This product is considered relevant in contexts involving lower-energy forage, which are conditions where growth may otherwise be limited.”


Quick Fact: Support for Suboptimal Growth Trajectories.

Regulatory References

  1. DailyMed official product information

Eligibility and Restrictions for Use

Revalor-G is a veterinary implant containing trenbolone acetate and estradiol that is strictly intended for use in specific categories of beef cattle.

Eligible Populations

Use is restricted to growing beef steers and heifers on pasture (including stocker, feeder, and slaughter cattle). The regulatory approval covers only a single implantation event per animal within this phase.

Prohibited Use (Contraindications)

This implant must not be used in the following populations, as effectiveness and safety have not been established or their use is explicitly prohibited by official labeling:

  • Animals intended for subsequent breeding (including heifers or cows).
  • Dairy cows or any dairy animals.
  • Veal calves or beef calves less than 2 months of age.

Note: This product is not approved for repeated implantation (re-implantation) in growing beef steers and heifers on pasture.

What should I know about interactions with other medicines?

Official Interaction Profile of Revalor-G

The official regulatory documentation for Revalor-G, a veterinary implant containing Estradiol and Trenbolone acetate, outlines interaction information primarily through its usage restrictions. The primary constraint is the absence of documented chemical interactions with co-administered medicinal products.

Documented Interaction Patterns

The official regulatory label does not specify any instances of classical drug–drug, metabolic, or pharmacokinetic interactions with other substances. This means that the regulatory documentation does not describe:

  • Interactions mediated by enzymes or drug transporters (e.g., CYP or P-gp) that would alter the levels or exposure of the active ingredients.
  • Pharmacodynamic interactions that would create additive or synergistic effects with other veterinary agents.
  • Mandatory administration timing rules requiring separation from other medicines or products.
  • Interactions with specific feed components, supplements, or herbal products.

Interaction-Related Restrictions and Prohibitions

While the regulatory data does not list specific drug combinations as contraindicated, it establishes explicit and formal constraints based on the type of animal. These constraints function as regulatory prohibitions on use:

  • Prohibited Use by Population: The implant is strictly prohibited and must not be used in dairy cows.
  • The use of Revalor-G is also formally prohibited in veal calves and breeding animals (bulls or heifers intended for breeding).

This structure confirms that the interaction-related profile of Revalor-G is defined by regulatory mandates governing its intended species and product type, rather than by chemical interactions with co-administered medicines.

Mechanism of Action

How Revalor-G Works


Steroid Receptor-Mediated Signaling

The active ingredients, trenbolone acetate (an androgen) and estradiol (an estrogen), act by binding to their specific steroid hormone receptors within target cells, such as those in skeletal muscle tissue. This engagement initiates gene transcription changes which affect processes related to growth and metabolism.


Modulation of the Somatotropic Axis

Estradiol primarily exerts its effects indirectly by stimulating the somatotropic axis, a key system involving growth hormone (GH). This action significantly increases the production and circulation of Insulin-like Growth Factor-I (IGF-I), a major mediator of systemic growth. This modification of an early molecular step influences systemic physiological consequences.


Direct Skeletal Muscle Anabolism

Trenbolone acetate (TBA) and its active metabolite have a more direct influence on muscle tissue by stimulating quiescent satellite cells. These cells proliferate and fuse with existing muscle fibers, donating their nuclei to support increased protein synthesis, which is the foundational mechanism for tissue accretion. This cascade modifies early molecular steps that result in the promotion of a net increase in protein accretion (nitrogen retention) over degradation.


Anti-Catabolic Pathway Effects

TBA also engages mechanisms that limit the negative impact of excessive mediator activity by decreasing the circulation of cortisol, a stress hormone known to promote muscle protein breakdown (catabolism). This adjustment within key pathways results in supporting the maintenance of protein turnover homeostasis, thereby influencing the anabolic signaling ratio.

Dosage and Administration Information

How to Use Revalor-G

Revalor-G is utilized according to a single-use protocol designed to provide sustained hormonal delivery over the course of a cattle feeding period. The general principles of its use are defined by its fixed-dose form, administration route, and extended-release mechanism.


Administration Scope and Dosing

The approved route of administration is exclusively subcutaneous (S.C.). This process requires the implant to be placed beneath the skin in the ear (the auricle), which is the designated anatomical site for administration.

Feature Detail
Dosing Schedule One full implant per animal is the standard dose, containing a fixed strength of 40 mg of Trenbolone acetate and 8 mg of Estradiol.
Frequency The product is a single administration event, typically performed at the initiation of the feeding period. Re-implantation is not approved.

Procedural and Use Constraints

Administration requires the use of a special implanting tool (implant gun) designed for the cartridge. Prior to use, the skin at the puncture site must be cleansed. The implant's integrity must be maintained; the pellets must not be broken or crushed, and they must be deposited in a single row to ensure proper sustained-release function.

The product is only to be used in growing beef steers and heifers on feedlots. Its use is prohibited in animals intended for subsequent breeding or in dairy cows. These instructions define the standardized procedure for proper delivery.

Recent Clinical Evidence

Research evidence / Overview of studies

This section summarizes the research that has explored how the compound, Revalor-G (a combination of trenbolone acetate and estradiol), may influence growth in pasture-fed cattle, including steers and heifers.

Research on Weight Gain Outcomes

Clinical trials have evaluated the compound's potential to increase the rate of weight gain. In a study comparing Revalor-G against non-implanted controls, implanted steers and heifers exhibited a higher average daily weight gain over the grazing season. For example, some grazing studies reported that cattle receiving the implant gained an average of an additional 23 pounds compared to non-implanted control cattle.

  • Researchers observed that the most pronounced differences in gain often occurred early in the study period.
  • The compound's profile was also examined in comparison to other implant types, with some analyses suggesting greater overall gains compared to products containing only estrogenic compounds.

Safety Profile and Tolerability Research

The safety profile was a key focus of clinical evaluations. The active ingredients are designed for a slow-release delivery system when administered as an implant under the skin of the ear.

  • Studies performed for regulatory review supported the safety and effectiveness of the implant for its intended use.
  • Regulatory authorities have determined that no withdrawal period is required before slaughter when the implant is used according to its labeling.
  • The product is not approved for use in dairy cows, beef calves less than two months of age, or animals intended for subsequent breeding, as safety and effectiveness have not been established in these populations.

Frequently Asked Questions (FAQ)

Common questions about Revalor-G (FAQ)

Q: How long does the effect of a single Revalor-G implant last?

A: According to the official product information, the Revalor-G implant is designed for an extended-release mechanism. This provides sustained hormonal delivery over the feeding period. Product information notes the implant remains effective for at least 120 days.

Q: What does 'no withdrawal period required' officially mean for Revalor-G?

A: Regulatory authorities have determined that Revalor-G, when used according to its label, requires a zero-day withdrawal period before slaughter. This means the amount of hormone residue remaining in the edible tissue is extremely small. The levels are below the established safe threshold for human consumption.

Q: What does the term 'stocker cattle' mean in the context of Revalor-G use?

A: The term 'stocker cattle' refers to one of the approved target animal populations for this product. Stocker cattle are included in the group of growing beef steers and heifers on pasture, alongside slaughter and feeder cattle, for which the use of Revalor-G is indicated.

Q: Why is Revalor-G explicitly labeled 'Not for use in humans'?

A: The label 'Not for use in humans' is a mandatory safety instruction due to the nature of the product's ingredients. Safety documentation specifies that the ingredients pose health hazards for humans, including the potential to cause cancer and damage fertility.

Q: Why does Revalor-G contain both a trenbolone compound and estradiol?

A: The decision to combine trenbolone acetate and estradiol is based on clinical research. Research examined this dual-hormone strategy, noting it is associated with superior anabolic outcomes and feed efficiency compared to single-hormone formulations.

Q: What is the difference between Revalor-G and other Revalor products like Revalor-H?

A: Revalor-G is a specific, low-dose formulation intended for growing steers and heifers on pasture. Other Revalor products, such as Revalor-H, contain different, often higher, hormone strengths and are approved for cattle in different production phases, such as those confined to a feedlot.

Q: How does the potency of Revalor-G compare to other cattle implants?

A: Official information indicates that Revalor-G is considered a low-dose, combination implant within the larger family of hormonal growth promotants. It is specifically formulated for use in stocker cattle on pasture, which are typically fed lower-energy rations.

Q: What is the typical timeframe for seeing results after using Revalor-G?

A: Studies examining Revalor-G observed that the most pronounced differences in weight gain compared to non-implanted animals often occurred relatively early in the study period following implantation. While the effect lasts for months, the time frame for noticeable results can vary depending on individual animal factors and diet.

Q: What happens if a Revalor-G implant is lost or falls out of the ear?

A: Expelled or lost implants are considered an administration defect that can lead to reduced effectiveness and performance loss in the animal. Official guidelines emphasize the need for careful technique and immediate palpation after placement to ensure the implant is properly secured beneath the skin of the ear.

Q: Are there research studies available on the long-term effects of Revalor-G?

A: Research evidence suggests that implanting stocker cattle with Revalor-G does not negatively affect the animals’ subsequent performance. This includes their ability to gain weight and finish during the later feedlot stage.

Q: Is there a difference in the performance of Revalor-G in steers versus heifers?

A: The official label indicates that Revalor-G is approved for both growing beef steers and heifers on pasture. While the product is indicated for both sexes, the expected rate of gain can vary depending on the individual animal's sex, genetics, and environment.

Q: Does Revalor-G affect the quality grade or carcass characteristics of the cattle?

A: According to the official product information, research findings indicate Revalor-G use is not expected to affect the final carcass quality or grading characteristics when used correctly in pasture cattle.

Q: Is it normal for the implant to be visible or palpable under the skin?

A: Official administration guidelines recommend that the site of implantation be physically palpated after the procedure. This is done to ensure the pellets are properly placed and aligned subcutaneously (beneath the skin) in the ear.

Q: Why is Revalor-G not to be used in veal calves?

A: The use of Revalor-G in veal calves is explicitly prohibited on the official label. This regulatory restriction is in place because the safety and effectiveness of the product have not been established in that specific, young animal population.

Q: Does Revalor-G contain any antibiotic components?

A: The official regulatory description lists the composition of Revalor-G. It lists the active ingredients as trenbolone acetate and estradiol. The label does not list any antibiotic components in the formulation.

Q: Are there guidelines for what to do if a person accidentally handles Revalor-G without proper protection?

A: Safety documentation outlines specific first-aid measures for accidental human exposure, which include actions such as flushing the skin with soap and water and seeking medical attention for any exposure type.

Q: Can Revalor-G be used in animals on low-quality forage?

A: Product information suggests the implant is suitable for use with various types of forage, including its use to support weight gain in marginal pasture situations.

How should Revalor-G be stored and disposed of?

The storage and disposal of Revalor-G implants must adhere strictly to official regulatory guidelines to maintain product quality.

Storage Conditions

  • Unopened Product: Store at or below 25 C (77 F). Excessive heat and humidity must be avoided.
  • Opened Cartridges: Store opened cartridges in the foil pouch under refrigeration (2 C to 8 C) and protected from light.
  • Stability Limit: Do not use the opened, refrigerated product after six months of storage.
  • Safety: The product must be kept out of reach of children and is designated Not for Use in Humans.

Disposal

Disposal of unused implants and waste materials must be carried out according to prescribed Federal, State, and Local guidelines for pharmaceutical waste. Do not attempt salvage of the implanted site for human or animal food.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Revalor-G found in:

A-Z Index: